An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022

L Crocetti, G Floresta, A Cilibrizzi, MP Giovannoni - Molecules, 2022 - mdpi.com
Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the
treatment of inflammation-based diseases. Several scientific advancements, by both …

[HTML][HTML] Puerarin: a potential natural neuroprotective agent for neurological disorders

X Liu, R Huang, J Wan - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Puerarin is an isoflavone compound derived from Pueraria lobata in traditional Chinese
medicine. Accumulating evidence has indicated that puerarin demonstrates multiple …

TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis

V Majumder, JM Gregory, MA Barria, A Green, S Pal - BMC neurology, 2018 - Springer
Background Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are
incurable, progressive and fatal neurodegenerative diseases with patients variably affected …

[HTML][HTML] Efficient machine learning approach for volunteer eye-blink detection in real-time using webcam

PA de Lima Medeiros, GVS da Silva… - Expert Systems with …, 2022 - Elsevier
The progressive diminishment of motor capacities due to Amyotrophic Lateral Sclerosis
(ALS) causes a severe communication deficit. The development of Alternative …

Multi-sided platform and data-driven care research: A longitudinal case study on business model innovation for improving care in complex neurological diseases

D Fürstenau, S Klein, A Vogel, C Auschra - Electronic Markets, 2021 - Springer
Multi-sided platforms in healthcare often focus their business model on standardizing care
for wide-spread, chronic diseases. However, there is a lack of knowledge surrounding …

Emerging novel approaches for the enhanced delivery of natural products for the management of neurodegenerative diseases

A Bandiwadekar, J Jose, M Khayatkashani… - Journal of Molecular …, 2022 - Springer
Neurodegenerative diseases (NDs) such as Alzheimer's disease, Parkinson's disease,
Huntington disease, amyotrophic lateral sclerosis, and prion disease affect any part of the …

Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients' view?

C Lacroix, R Guilhaumou, J Micallef, G Bruneteau… - Revue …, 2023 - Elsevier
Cannabis may have therapeutic benefits to relieve symptoms of amyotrophic lateral
sclerosis (ALS) thanks to its pleiotropic pharmacological activity. This study is the first to …

Current advancements related to phytobioactive compounds based liposomal delivery for neurodegenerative diseases

KB Khot, G Gopan, A Bandiwadekar, J Jose - Ageing Research Reviews, 2023 - Elsevier
Neurodegenerative diseases are the most widely affected disease condition in an aging
population. The treatment available reduces the elevated manifestations but is ineffective …

Multidisciplinary care in amyotrophic lateral sclerosis: a systematic review and meta-analysis

FEO de Almeida, AK do Carmo Santana… - Neurological …, 2021 - Springer
Multidisciplinary care (MDC) has been the most recommended approach for symptom
management in amyotrophic lateral sclerosis (ALS) but there is conflicting evidence about its …

Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling

B Arjmand, S Kokabi Hamidpour, Z Rabbani… - Frontiers in …, 2022 - frontiersin.org
Amyotrophic lateral sclerosis is a pernicious neurodegenerative disorder that is associated
with the progressive degeneration of motor neurons, the disruption of impulse transmission …